AMMF’s Hybrid 2025 European Cholangiocarcinoma Conference
AMMF’s welcomes Jazz Pharmaceuticals as a sponsor of the 2025 conference.
Highlighting Jazz’s Commitment to the Rare Cancer Community
Tomas Skacel, MD, PhD
Vice President, Medical Affairs for the
Europe and International region
at Jazz Pharmaceuticals.
Jazz Pharmaceuticals is delighted to be sponsoring AMMF’s 2025 European cholangiocarcinoma conference.As a global biopharmaceutical company serving patients in almost 100 countries, we are focused on developing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully.
Focusing on unmet need as our north star is a useful compass to make sure that all we do is delivering true value to patients. We feel motivated and passionate therefore to direct our research and development efforts towards rare cancers. Many rarer cancers have complex pathophysiology, are often aggressive, with poor prognoses, and we use our expertise in developing innovative medicines to make a difference to the rare cancer community.
Working in rare cancers doesn’t come without its challenges. Small patient populations make designing registration trials complex, running them costly and recruiting patients challenging — a task that can be likened to finding the proverbial needle in a haystack. Uncertain outcomes make clinical trial success elusive, and even when successful, navigating the regulatory landscape requires expertise, substantial investment and resources. However, when it comes to progress in rare cancers, we also know that gains can be incredibly meaningful for patients. Transformative breakthroughs in cancer treatment are often built on a foundation of incremental gains. Each step forward, no matter how seemingly small, represents a victory for patients and their loved ones. Whether it’s extending survival by months to provide patients with more time, improving quality of life, or reducing treatment-related side effects, these incremental gains pave the way for lasting impact.
Jazz recently supported the Union for International Cancer Control’s World Cancer Day campaign, the 2025-27 theme of which is “United by Unique”. The campaign reminds us that behind every cancer diagnosis lies a unique human story, and that a people-centered approach to cancer care that fully integrates each individual’s unique needs, with compassion and empathy, leads to the best health outcomes. For the team at Jazz, we’re taking this theme to heart, and striving to consider the individual in every aspect of our work.
This intention feels particularly important for rare cancers. The theme also underscores the potential and importance of personalized innovative therapeutic approaches in rare cancers to lead to more effective and targeted therapies to improve patient’s lives. This conference, and beyond, we look forward to getting to know the community, its challenges and opportunities and considering ways we can further partner to help improve outcomes of rare cancer patients in the years to come.
Jazz Pharmaceuticals have supported AMMF’s 2025 Conference through a financial contribution only. They have not been involved in the content nor in any other aspect of the conference.
M-INT-JPC-2500002
